OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Lim on the Potential Role for Subcutaneous Amivantamab in EGFR-Mutant NSCLC

September 9th 2025

Sun-Min Lim, MD, PhD, discusses the potential adoption of first-line subcutaneous amivantamab plus chemotherapy in EGFR-mutant NSCLC.

Dr Rathkopf on the Rationale for Evaluating Niraparib Plus Abiraterone Acetate in HRR+ mCSPC

September 9th 2025

Dana E. Rathkopf, MD, discusses the purpose of evaluating niraparib plus abiraterone acetate in metastatic castration-sensitive prostate cancer.

Dr Monje on the Role of a Novel GD2-Directed CAR T-Cell Therapy in Diffuse Midline Glioma

September 9th 2025

Michelle Monje, MD, PhD, discusses the early efficacy of a novel GD2-directed CAR T-cell therapy for the treatment of children with diffuse midline glioma.

Dr Tarantino on the Efficacy of Adjuvant THP in HER2+ Breast Cancer

September 8th 2025

Paolo Tarantino, MD, PhD, discusses the efficacy and safety of adjuvant THP in patients with stage II to IIIA HER2-positive breast cancer.

Dr Gill on the Rationale for Surveying Patients With mCRC About Treatment Decision-Making

September 8th 2025

Sharlene Gill, BScPharm, MD, MPH, MBA, FRCPC, discusses the rationale for evaluating patient experiences and involvement in CRC treatment decision-making.

Dr Patel on Remaining Gaps in Biomarker Testing for Early-Stage Resected NSCLC

September 8th 2025

Sandip P. Patel, MD, discusses remaining gaps in biomarker testing and their implications for targeted therapies in early-stage NSCLC.

Dr Nieva on the Role of ADCs in the NSCLC Treatment Paradigm

September 8th 2025

Jorge Nieva, MD, discusses the current role and the effect antibody-drug conjugates have on the lung cancer treatment paradigm.

Dr Singhi on Responsibly and Effectively Leveraging Social Media for Patient Education in Oncology

September 8th 2025

Eric K. Singhi, MD, expands on how oncologists can work with patient advocacy groups on social media to improve patient education and engagement.

Dr Popat on the Rationale for Assessing JNJ-5322 in Relapsed/Refractory Myeloma

September 8th 2025

Rakesh Popat, MBBS, MRCP, FRCPath, PhD, details the mechanism of action and the impetus for assessing JNJ-5322 in relapsed/refractory multiple myeloma.

Dr Taub on the Benefits of a Multimodal Treatment Approach in Prostate Cancer

September 8th 2025

David Taub, MD, FACS, discusses how multidisciplinary care can optimize therapy selection for patients across different stages of prostate cancer.

Dr Liu on Updated Efficacy and Safety Data With Taletrectinib in ROS1+ NSCLC

September 7th 2025

Geoffrey Liu, MSc, MD, discusses updated efficacy and safety results with taletrectinib in ROS1-positive non–small cell lung cancer.

Dr Drilon on the Efficacy of Zidesamtinib Relative to Other ROS1 Inhibitors in Pretreated ROS1+ NSCLC

September 7th 2025

Alexander Drilon, MD, compares response rates with zidesamtinib with that of prior ROS1 inhibitors in pretreated patients with ROS1-positive NSCLC.

Dr Issa on Testing for NPM1 or KMT2A Alterations in AML

September 6th 2025

Ghayas C. Issa, MD, MS, discusses the optimal timing of and approaches to genetic testing for NPM1 and KMT2A alterations in AML.

Dr Gangaram-Panday on Definitive Chemoradiotherapy in Esophageal Cancer

September 5th 2025

Sanjiv Gangaram-Panday, PhD, discusses findings from a population-based cohort study of definitive chemoradiotherapy in esophageal adenocarcinoma.

Dr Eng on the Implications of a Real-World Study in KRAS G12C–Mutated CRC

September 5th 2025

Cathy Eng, MD, FACP, FASCO, discusses the clinical significance of a real-world study of KRAS G12C mutations on treatment outcomes in mCRC.

Dr Shadman on the Impetus for Assessing Zanubrutinib Plus Venetoclax in Previously Untreated CLL/SLL

September 5th 2025

Mazyar Shadman, MD, MPH, details the rationale for investigating the combination of zanubrutinib and venetoclax in treatment-naive CLL/SLL.

Dr Sfakianos on Addressing Unmet Needs With Intravesical Mitomycin in Recurrent, Low-Grade, Intermediate-Risk NMIBC

September 5th 2025

John P. Sfakianos, MD, discusses the rationale for evaluating mitomycin intravesical solution in recurrent, low-grade, intermediate-risk NMIBC.

Dr O’Shaughnessy on the Utility of the MammaPrint Assay in HR+ Breast Cancer

September 5th 2025

Joyce O’Shaughnessy, MD, discussed data that support the use of the MammaPrint assay in predicting chemotherapy benefit in HR-positive breast cancer.

Dr Tashi on Differentiating Characteristics of Elenestinib in Indolent Systemic Mastocytosis

September 5th 2025

Tsewang Tashi, MD, discusses the aspects of elenestinib that differentiate it from avapritinib in the management of indolent systemic mastocytosis.

Dr Loghavi on SOC Frontline Testing Approaches in MDS

September 5th 2025

Sanam Loghavi, MD, discusses standard-of-care frontline testing in myelodysplastic syndrome.